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Abstract
Background: Reversible inhibition of sperm under guidance (“RISUG®”) is a promising
intravasal male contraceptive.
Objective: An exploratory study was conducted with a concept of non-invasive,
transcervical, single-intervention and reversible contraception using RISUG® in
females.
Materials and Methods: In this experimental study, 60 adult Wistar albino female rats
weighing 150-155 g, 3-4 months old were divided into four groups: group I: sham-
operated control; group II: tubal occlusion with RISUG for 90 days; group III: tubal
occlusion with RISUG® for 90 days and reversal with dimethyl sulphoxide and group IV:
tubal occlusion with RISUG® for 90 days and reversal with 5% NaHCO3. Animals were
subjected to bilateral fallopian tube occlusionwith RISUG® and reversal with DMSOand
NaHCO3. The estrous cycle, fertility and histology of fallopian tube were evaluated.
Results: Group I showed 100% fertility during all mating schedules. Animals of
experimental groups indicated positive mating, but 0% fertility was evident following
30, 60, and 90 days of tubal occlusion. However, after reversal, fertility steadily
increased to normalcy in groups III (50% at 45 days, 80% at 105 days, 100% at 150 and
195 days) and IV (70% at 45 and 105 days, 100% at 150 and 195 days) animals. Group
II illustrated disorganized inner cell linings and eosinated RISUG® implant-filled lumen.
Reversal groups (III and IV) revealed complete restoration of cellular histo-architecture.
Regular estrous cycle was noticed in all experimental groups.
Conclusion: RISUG® is suitable for single intervention, intratubular, reversible
contraception in female rats.
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1. Introduction
Family planning issues are often a significant
cause of concern for global population. Unmet
need for family planning is crucial to securing
the well-being and sovereignty of women. The
unprecedented population growth has also
been considered as the primary drivers of
various ecological, societal threats and mass
species extinction (1). Hence, the concept
of contraception has a paramount impact
in regulating overpopulation (2). Males are
typically restricted to condoms and vasectomy;
consequently, females are often burdened
with the responsibility of population regulation
(3). The approaches for females are usually
achieved through barrier methods, hormonal,
non-hormonal, chemicals such as quinacrine,
intrauterine devices, tubectomy, and transcervical
sterilization. In India, sterilization methods
dominate over all other contraceptives in
females. Adolescents have their reproductive
careers ahead of them, they also require
to postpone or space pregnancies, which
requires reversible and non-invasive methods.
Female sterilization or tubectomy is meant
to be permanently associated with health
risk without preventing sexually transmitted
diseases. It is an irreversible method, which
can be reversed by canalization, but this is not
always successful. If pregnancy occurs after
the procedure, there is an increased risk for an
ectopic pregnancy (4). Thus, limitations are still
associated with tubectomy, and therefore, further
research on efficacy and reversibility is needed
to achieve better contraceptive modalities.
So, in the light of extensive use of tubectomy
along with drawbacks, there is still a lapse in
an ideally accepted contraceptive method in
terms of efficacy, safety, and reversibility for
females.
A polymer-based contraceptive, Reversible
Inhibition of Sperm Under Guidance (RISUG®)
is currently in advanced phase III clinical trials,
which could be an effective male contraceptive
with the potential of reversibility (5, 6). The
contraceptive activity of RISUG® as a potential
molecule along with safety, efficacy, non-toxicity,
and reversibility has been successfully confirmed
in animal models, viz., rats, rabbits, and langur
monkeys (5-12). Non-invasive approaches have
been applied successfully in monkeys for the vas
occlusion reversal (7, 12). Reversal with DMSO
and/or NaHCO3 has also been studied in rats
and rabbits proving its feasibility and safety up
to F1 generation with restoration of complete
fertility (6, 9-12). RISUG® exerts contraceptive
effects by occlusion at delivery site, lowers pH,
charges disturbance in gamete and excessive
generation of reactive oxygen species. Its in
vitro ovicidal properties also suggest RISUG® as
a potential female fertility-regulating agent (13,
14).
Thus, this experimental study has been
designed with an objective to develop a
concept of non-invasive, transcervical, single
intervention, and reversible female contraceptive
using RISUG® as a fallopian tube implant.
Therefore, in the present investigation, the
contraceptive efficacy of RISUG®-induced tubal
occlusion and functional reversal with dimethyl
sulphoxide (DMSO) and NaHCO3 was carried out
following a short-term reversal in female albino
rats.
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2. Materials and Methods
2.1. Drug
RISUG®, a copolymer of styrene and maleic
anhydride (1:1 ratio), was prepared through cobalt
60 gamma irradiation of styrene and maleic
anhydride monomer in the presence of nitrogen
in ethyl acetate at a dose of 0.2-0.24 mega rad
for every 40 g of polymer at a dose rate of 30-
40 rad/sec. After that, it was precipitated, dried,
and stored in a vacuum desiccator, dissolved in
DMSO solvent (15). The drug was provided by
Prof. S. K. Guha, School of Medical Science and
Technology, Indian Institute of Technology, New
Delhi, India.
2.2. Animals
Adult Wistar albino female rats (Rattus
norvegicus), weighing 150-155 gr, 3-4 months
old were used for the study. The animals were
hygienically maintained at the Departmental
Experimental Animal facility, with well-regulated
photoperiod (12 hr light: 12 hr dark), in individual
polypropylene cages (size 43 × 27 × 15 cm).
The temperature in animal house was adjusted
at 23 ± 2°C, and the relative humidity ranged
between 32 and 70%. Animals were fed twice
a day with rat pellet diet (Ashirwad Industries
Limited, Chandigarh, India) and safe drinking
water ad libitum.
2.3. Experimental design
A total of 60 animals were included in this
experimental study. Group I (Sham-operated
control) contained 30 animals (Sub-groups Ia,
Ib, and Ic (n = 10/each)), while groups II, III,
and IV contained 10 animals each. Animals
in the sub-groups served as parallel controls
for groups II-IV to determine the fertility
among the experimental groups. In group
I, the animals were subjected to bilateral
tubal occlusion, but no drug was injected
and served as control; group II: the animals
were subjected to tubal occlusion with 5-
7 µL of RISUG®, bilaterally, and euthanized
after 90 days; group III: the animals were
subjected to tubal occlusion reversal with
DMSO after 90 days of occlusion; group IV:
the animals were subjected to tubal occlusion
reversal with 5% NaHCO3 after 90 days of
occlusion. Same animals were repeated
at every mating schedule. The repeated
mating ensured the fertility at given interval.




Animals of groups II-IV were subjected
to bilateral fallopian tube occlusion,
after an overnight fasting, under sodium
thiopentone anesthesia (20 mg/kg body
weight, intraperitoneal; Thiosol Sodium: Neon
Laboratories Ltd., Mumbai, India). Skin was
disinfected and lateral incision was made
to locate the uterus. Using the microsyringe
fitted with blunt needle (26 G), a 5-7 µL of
therapeutic standardized dose of RISUG® was
injected into each fallopian tube to block the
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median to distal segment (antegrade). RISUG®
polymerization was catalyzed by application
of normal saline and solidified on contact
with luminal fluid. The tube was placed in
its original position and incision was closed
by catgut suture in the inner and by silken
suture in the outer skin. Postoperative care
was acquired through antibiotic Ceftriaxone
injection 0.025 mg/ml i.p. (Cefoat, A to Z
Pharmaceuticals Ltd., Gujarat, India), anti-
inflammatory Meloxicam 0.025 ml i.p. (Melonex,
Intas Pharmaceuticals Ltd., Gujarat, India), and
topical HealexPlus Spray (Shreya Life Sciences
Pvt. Ltd., Mumbai, India). Until healing, the
animals were supervised and provided proper
bedding, feed, and water. The fallopian tubes
of group I animals (sham-operated control) were
exposed in a similar way, but no drug was
injected.
2.4.2. Tubal occlusion reversal
The reversal was performed following 90
days of tubal occlusion. The tubes were
exposed in a similar way as that of tubal
occlusion and injected bilaterally with 250-
500 µL of DMSO in group III and 500-700 µL
of 5% NaHCO3 in group IV animals to liquefy
RISUG® (11). The dissolution of RISUG® was
confirmed by free flow of the DMSO and
5% NaHCO3 through the entire length of
tube and DMSO and 5% NaHCO3 swill out
due to the positive pressure emanating from
the tube through the vagina via uterus. The
tube was returned to original position and
postoperative care was provided as described
previously.
2.5. Parameters
2.5.1. Monitoring of estrous cycle
Estrous cycle was screened by taking
vaginal swabs (16). Vaginal secretion was
collected with the sterile glass dropper
filled with 10-20μL of normal saline (0.9%
NaCl) by inserting the tip smoothly into the
vagina and gently flushing the saline in and
drawing it back into the glass dropper. The
vaginal fluid was uniformly spread on the
marked slides and observed under the light
microscope (Model: DM1000, Leica Wetziar,
Germany).
2.5.2. Fertility test
Periodical fertility tests were conducted in
sham operation, tubal occlusion, and reversal
groups as per following schedule, viz., 30, 60,
and 90 days of tubal occlusion and 45, 105,
150, and 195 days of tubal occlusion reversal
by cohabitating the experimental females with
the proven fertile male rats at 1:1 ratio. Mating
success was confirmed by the appearance of
vaginal plug and presence of spermatozoa
in the vaginal smear examined under light
microscope (Model: DM1000, Leica Wetziar,
Germany). The number of females that delivered
and the litter size was recorded for calculating
fertility.
2.5.3. Histology of fallopian tube
Fallopian tube from all animals was removed
surgically at scheduled sacrification and fixed
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overnight in 4% paraformaldehyde, dehydrated
in ethanol, cleared in xylene, and embedded in
paraffin wax. Next, 5-µm thin sections were
cut, fixed, spreaded on Mayer’s albumin-
coated slides and processed for hematoxylin
and eosin staining for light microscopic
observations (Model: DM1000, Leica Wetziar,
Germany).
2.6. Ethical considerations
The experimental protocol was approved
by the Institutional Animal Ethics Committee
(IAEC) under certificate no. UDZ/IAEC/I/02,
dated 03.07.2015, Department of Zoology,
University of Rajasthan, Jaipur, India. Animals
were maintained under perfect veterinary
supervision, and the guidelines of “Committee
for the Purpose of Control and Supervision
of Experiments on Animals” (17) were strictly
followed.
2.7. Statistical analysis
Data are represented as mean ± standard
deviation (SD). One-way analysis of variance
(ANOVA) test followed by post-hoc (Duncan’s
new multiple range test) procedure was
applied for statistical comparisons, wherever
applicable. Data were analyzed using the
Holm-Sidak multiple comparison test to
detect the inter-group difference using the
statistical software SPSS, version 10.0 (SPSS Inc.,
Chicago, IL, USA). P < 0.05 was considered as
significant.
3. Results
3.1. Characteristics of estrous cycle
The estrous cycle phases, that is, proestrus,
estrus, metestrus, and diestrus were found to be
comparable to the control. Thus, the estrous cycle
length was normal, 4-5 days long in the animals of
groups II-IV when compared with group I animals
(Figure 1).
3.2. Fertility test
The presence of spermatozoa in the vaginal
smear along with vaginal plug confirmed
successful mating in all groups. Animals of
group I showed 100% fertility during all mating
schedules of pre-injection, tubal occlusion,
and reversal periods. Animals of group II-
IV indicated positive mating, but 0% fertility
was evident following 30, 60, and 90 days of
tubal occlusion. In groups III and IV, animals
exhibited 0% fertility following tubal occlusion and
gradual increase in fertility following reversal
was observed. However, group III animals
exhibited gradual increase in fertility (50%
at 45 days, 80% at 105 days, 100% at 150
days, and 100% at 195 days) following tubal
occlusion reversal with DMSO. Group IV animals
indicated a gradual enhancement in fertility
(70% at 45 days, 70% at 105 days, 100% at 150
days, and 100% at 195 days) following tubal
occlusion reversal with NaHCO3 during all mating
schedules, respectively. No remarkable changes
were observed in the mean litter size in all
experimental groups as compared with group I
(Table I).
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3.3. Histology of fallopian tube
The fallopian tubes of group I animals
revealed normal histological features, illustrating
a definite inner mucosa, circular and longitudinal
muscularis, and outer serosa. The tubal isthmus
was noticed with thick wall, more muscular with
narrow lumen and short mucosal folds (Figure
2A). The fallopian tubes of group II animals
revealed distorted cellular configuration along
with disordered epithelial cells at certain places
in the implanted region; nonetheless, normal
histological architecture of mucosa, muscularis,
and serosa were observed. In the implanted
isthmus, mucosal folds were irregular with
disturbed structural pattern. The accumulation
of shedded and detached epithelial tissues
from mucosal folds and the isthmic lumen filled
with eosinated RISUG® implant were observed
(Figure 2B). The fallopian tubes of reversal
groups (III and IV) animals revealed complete
regeneration of the epithelial linings when
compared with the controls (Figures 2C and
2D).






Tubal occlusion Tubal occlusion reversal
0 day 30 days 60 days 90 days 45 days 105 days 150 days 195 days
No. of females delivered/mated
Ia 10/10 10/10 10/10 10/10 - - - -
II 10/10 0/10 0/10 0/10 - - - -
Ib 10/10 10/10 10/10 10/10 10/10 10/10 10/10 10/10
III 10/10 0/10 0/10 0/10 05/10 08/10 10/10 10/10
Ic 10/10 10/10 10/10 10/10 10/10 10/10 10/10 10/10
IV 10/10 0/10 0/10 0/10 07/10 07/10 10/10 10/10
Litter size
Ia 5.00 ± 0.89 5.10 ± 0.83 4.20 ± 0.87 4.40 ± 1.11 - - - -
II 4.50 ± 0.50 0 0 0 - - - -
Ib 4.80 ± 0.75 4.90 ± 0.83 4.80 ± 1.08 5.00 ± 1.18 4.10 ± 0.70 4.20 ± 1.08 5.10 ± 0.70 4.50 ± 1.03
III 4.70 ± 1.00 0 0 0 5.00 ± 0.89 4.90 ± 0.83 4.40 ± 0.80 4.20 ± 1.33
Ic 4.50 ± 0.81 4.60 ± 0.92 5.00 ± 0.63 4.30 ± 0.90 4.70 ± 1.10 4.80 ± 0.87 5.10 ± 0.94 4.30 ± 0.78
IV 4.40 ± 0.49 0 0 0 4.80 ± 0.83 4.20 ± 0.99 4.10 ± 0.70 4.60 ± 1.02
% Fertility
Ia 100 100 100 100 - - - -
II 100 0 0 0 - - - -
Ib 100 100 100 100 100 100 100 100
III 100 0 0 0 50 80 100 100
Ic 100 100 100 100 100 100 100 100
IV 100 0 0 0 70 70 100 100
All data are expressed as Mean±SD. Group Ia, Ib, Ic: sham-operated control; group II: tubal occlusion with RISUG® for 90 days;
group III: tubal occlusion with RISUG® for 90 days and reversal with DMSO; group IV: tubal occlusion with RISUG® for 90 days
and reversal with 5% NaHCO3
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Figure 1. Estrous cycle phases (days) of female rats following sham operation, tubal occlusion with RISUG®, and its reversal
with DMSO and NaHCO3. Group I (control group) was further divided into three sub-divisions for comparing the fertility with the
experimental groups (II, III, and IV). Thus, 10 animals were chosen randomly for comparing estrous phases with other experimental
groups (II, III, and IV).
Figure 2. Histology of rat fallopian tube. (A) Group I (sham-operated control) rat showing normal histological features, illustrating
a well-defined inner mucosa, muscularis, and outer serosa. The tubal isthmus appears thick-walled, more muscular, with narrow
lumen and short mucosal folds. (B) Group II (tubal occlusion with RISUG®for 90 days) rat showing shedded epithelium with blunt
and low villi and eosinated implant in luminal epithelial cells of the isthmus region. (C) Group III (tubal occlusion with RISUG® for 90
days and its reversal with DMSO) rat showing unaltered features as compared to control. (D) Group IV (tubal occlusion with RISUG®
for 90 days and its reversal with NaHCO3) rat showing unaltered features as compared to control (HE x 200). Scale Bar = 50 µm.
S: Serosa; Mu:Muscularis; M: Mucosa; L: Lumen; R*: RISUG implanted.
4. Discussion
The results of the present investigation
demonstrate that the RISUG®-induced complete
sterility following 90 days of tubal occlusion
and reversibility with both DMSO and NaHCO3
without any changes in estrous cyclicity. Histology
of fallopian tube revealed distortion of epithelial
cell configuration in the implanted site in tubal
occluded animals and complete regeneration
of the epithelial linings following reversal.
The alarming population growth demands
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better contraceptive modalities to expand
the contraceptive selections for both sexes.
Tubectomy is an extensively exercised surgical
contraceptive, yet post-tubectomy pregnancies
and abnormalities have been reported (18). The
sale and use of Essure®, the first US Food and
Drug Administration (FDA)-approved standard
transcervical procedure was restricted due
to Essure problems (19). The second FDA-
approved Adiana® has also been associated
with menstruation cramping, intractable pain,
tubal perforations, and ectopic pregnancies (4,
20-22). Quinacrine sterilization is less acceptable
as it was proved as a mutagen (23, 24). Recently
discovered polidocanol foam (PF) also resulted in
nonsurgical female contraception through tubal
occlusion via multiple treatments in baboons (25)
and rhesus (26). An ex vivo macaque fallopian
tube has also been employed for assessing the
PF outcomes (27). Conversely, further research
has been warranted to induce permanent tubal
occlusion with a single transcervical intervention
and successful reversibility. These reports
exceedingly warrant substitute contraceptives
with minimal invasive approach.
In the present study, the RISUG® has been
investigated as a single intervention approach
with a possibility of reversal. The drug was
injected through micro-syringe via distal section
(infundibulum with fimbriae) occluding the tubes
and consequently hindering capacitation. The
fimbriae have crucial role in sweeping the
oocyte into the fallopian tubes for fertilization.
If they no longer function then the oocyte
never makes it to its destination for fertilization
(28). RISUG® implants in fallopian tubes appear
to block the tubes on solidification, alter the
pH and osmolarity, thus, generating unfavorable
conditions for fertilization. As reproductive tract,
pH is the chief determinant in the sperm-ova
interaction; an elevated pH can adversely affect
cervical mucus and sperm cell motility leading to
infertility (29). The implants may adversely affect
the ova morphology on interaction, making it non-
viable by generating reactive oxygen species. In
order to achieve reversal, the RISUG® blockage
was flushed out favorably through DMSO and
NaHCO3, normalizing the fallopian tubes as well
as oocyte movement, subsequently resuming
fertility with normal F1 progeny. Simultaneously,
various parameters proved safety, efficacy, and
reversibility of the procedure (9, 10, 13). Further
investigations in a suitable non-human primate
model will open avenues for clinical trials to
adjudge suitability of RISUG® as a non-invasive
female contraceptive.
5. Conclusion
RISUG® proved to be suitable for single
intervention, intratubular, reversible contraception
in female rats.
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